Sinopharm Tech Holdings Limited provides earnings guidance for the year ended 30 June 2023. The Group is expected to record the loss attributable to equity holders of the Company for the year ended 30 June 2023 to decrease in the range between 80% and 90%, as compared with the loss attributable to equity holders of the Company of approximately HKD 88.0 million for the year ended 30 June 2022. The significant decrease in loss was mainly attributable to, among other things, (i) gain on disposal of locked-up shares related to profit guarantee; (ii) gain on settlement of loans by shares issued; (iii) less impairment losses on goodwill; and (iv) the company having strengthened its efforts in cost control, resulting in less administrative and operating expenses.